Who are AK117 in combination with AK112's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ponatinib + Blinatumomab, GST-HG141, SHR-A1811 for Injection, BAT8001 for injection, Amivantamab Intravenous, VB4-845 Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ak117-in-combination-with-ak112.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

AK117 in combination with AK112 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AK117 in combination with AK112 (AK117 in combination with AK112) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific monoclonal antibody. Area: Oncology.

phase 3 Bispecific monoclonal antibody PD-1/LAG-3 (AK117) and PD-L1/TIM-3 (AK112) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AK117 in combination with AK112 (AK117 in combination with AK112) — Akeso. AK117 and AK112 are bispecific antibodies that simultaneously engage immune checkpoint pathways to enhance anti-tumor T-cell responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AK117 in combination with AK112 TARGET	AK117 in combination with AK112	Akeso	phase 3	Bispecific monoclonal antibody	PD-1/LAG-3 (AK117) and PD-L1/TIM-3 (AK112)
Ponatinib + Blinatumomab	Ponatinib + Blinatumomab	Gruppo Italiano Malattie EMatologiche dell'Adulto	phase 3	Tyrosine kinase inhibitor, Bispecific monoclonal antibody	BCR-ABL1, CD19, CD3
GST-HG141	GST-HG141	Fujian Akeylink Biotechnology Co., Ltd.	phase 3	Bispecific monoclonal antibody
SHR-A1811 for Injection	SHR-A1811 for Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	phase 3	Bispecific monoclonal antibody; dual checkpoint inhibitor
BAT8001 for injection	BAT8001 for injection	Bio-Thera Solutions	phase 3	Bispecific monoclonal antibody
Amivantamab Intravenous	Amivantamab Intravenous	Janssen Research & Development, LLC	phase 3	Bispecific monoclonal antibody	EGFR and MET
VB4-845 Injection	VB4-845 Injection	Qilu Pharmaceutical Co., Ltd.	phase 3	Bispecific monoclonal antibody	VEGF and HER2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific monoclonal antibody class)

Akeso · 1 drug in this class
Bio-Thera Solutions · 1 drug in this class
Fujian Akeylink Biotechnology Co., Ltd. · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class
Shanghai JMT-Bio Inc. · 1 drug in this class
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · 1 drug in this class
Xianmin Song, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AK117 in combination with AK112 — Competitive Intelligence Brief. https://druglandscape.com/ci/ak117-in-combination-with-ak112. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab